news
Lundbeck disagrees with the Statement of Objections issued by the European Commission
25 July 2012 | By H. Lundbeck A/S
The European Commission has issued a Statement of Objections to Lundbeck...
List view / Grid view
H. Lundbeck A/S
news
Lundbeck plans to establish a more flexible commercial organisation in Europe
14 June 2012 | By H. Lundbeck A/S
Lundbeck proposes to restructure its commercial organisation in Europe to build a more flexible commercial infrastructure and to maintain cost control...
news
Lundbeck’s Lu AE58054 meets primary endpoint in large placebo-controlled clinical proof of concept study in people with Alzheimer’s disease
29 May 2012 | By H. Lundbeck A/S
The pivotal clinical programme is in planning...
news
Lundbeck establishes a sponsored Level I ADR programme in the US
24 May 2012 | By H. Lundbeck A/S
H. Lundbeck A/S announced that the company has established a sponsored Level I ADR programme in the United States...
news
Capital increase in Lundbeck as a result of employee warrant programme
21 May 2012 | By H. Lundbeck A/S
Lundbeck increases its share capital by 593 shares as a result of employee warrant exercise...
news
Statistically significant clinical phase III results of Lu AA21004
14 May 2012 | By H. Lundbeck A/S
H. Lundbeck A/S announced positive top-line results from three recently completed phase III clinical studies of Lu AA21004...
news
New data presented at the 2012 Annual Meeting of the APA
8 May 2012 | By H. Lundbeck A/S
Lu AA21004 may have positive effect on cognitive dysfunction in patients with major depressive disorders...
news
Results of clinical phase III study of once-monthly aripiprazole IM depot formulation for the treatment of schizophrenia presented at APA
7 May 2012 | By H. Lundbeck A/S
H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced results from a clinical phase III clinical trial evaluating the efficacy, safety and tolerability of once-monthly aripiprazole intramuscular (IM) depot formulation for the maintenance treatment of adults with schizophrenia. Trial results were presented in four poster presentations at…
news
New product launches on track and revenue continues to show growth, excluding Lexapro (US)
2 May 2012 | By H. Lundbeck A/S
H. Lundbeck A/S reports first quarter revenue of DKK 3,442 million...
news
New incentive plans in the Lundbeck Group
29 March 2012 | By H. Lundbeck A/S
The Board of Directors of H. Lundbeck A/S has resolved, pursuant to the authorisation in article 4.4 of the company's articles...
news
Lundbeck awarded for ethical leadership in the pharmaceutical industry
29 March 2012 | By H. Lundbeck A/S
Lundbeck is becoming the first recipient of a new award for ethical leadership in the pharmaceutical industry...
news
Lundbeck appoints new vice president of business development
21 March 2012 | By Lundbeck
Lundbeck has appointed Jacob Tolstrup as new vice president with responsibility for the company's business development...
news
Lundbeck strengthens ownership of desmoteplase by acquiring Paion’s remaining rights
28 February 2012 | By H. Lundbeck A/S (Lundbeck)
Lundbeck acquires Paion's remaining rights to desmoteplase for EUR 20.1 million thereby further strengthening the control over desmoteplase...
news
Lundbeck strengthens its European organization
10 February 2012 | By H. Lundbeck A/S
Lundbeck bolsters its European organization with the appointment of João Rocha and Michael Quiqueran-Beaujeu...
news
Lundbeck awarded prize for world-class production
16 January 2012 | By H. Lundbeck A/S
H. Lundbeck A/S has crowned six years of focused efforts on productivity improvements with a silver medallion...
